Investing.com -- Morgan Stanley analysts visited National Resilience, a private contract development and manufacturing organization, outside Cincinnati, Ohio. The visit included meetings with senior management and a tour of the company's expanding facilities.

National Resilience, founded in 2020, provides manufacturing solutions for advanced therapies. The company's capabilities include biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules.

The company's clients include Eli Lilly (NYSE: LLY) and AstraZeneca. National Resilience manufactures Tirzepatide auto-injectors and vials for Eli Lilly, with Kwikpen production planned for the future. Management stated that over 60% of the biopharma industry's pipeline consists of injectable medicines, with a large portion delivered via devices.

National Resilience plans to invest over $400 million from 2023 to 2028 to expand its existing footprint. The company also invests in developing and training its workforce in Ohio. Training takes approximately three to six months for each employee.

The company operates two facilities north of Cincinnati. The West Chester site handles fill-finish and assembly/packaging. The Blue Ash site, currently under construction, will handle assembly/packaging.

The company currently has two active fill-finish lines, with three under construction. The two active lines are a Groninger line with capacity of approximately 40 million units per year and an Optima line with capacity of approximately 60 to 80 million units per year. The three lines under construction include two additional Optima lines and one Syntegon line with capacity of approximately 100 million units per year.

The newest fill-finish line costs approximately $100 million and can take three to four years to build. Some device components have an 18-month or longer lead time.

The company recently conducted a pilot project with Palantir (NYSE: PLTR) to minimize downtime on a fill-finish line.